SAFETY AND EFFECTIVENESS OF TRI VALENT INACTIVATED SPLIT VIRION INFLUENZA VACCINE IN PATIENTS WITH RHEUMATOID DISORD ERS

Antzeko izenburuak

• Efficacy, safety and immunogenicity of a trivalent inactivated split influenza vaccine in patients with rheumatic diseases
  nork: D. V. Bukhanova, et al.
  Argitaratua: (2018-07-01)
• Immunogenicity, Effectiveness, and Safety of Trivalent Inactivated Influenza Split Vaccine in Patients with Inflammatory Joint Diseases Receiving Modern Antirheumatic Therapy
  nork: M. M. Baranova, et al.
  Argitaratua: (2024-06-01)
• Immunogenicity, efficacy and safety of the three-valent inactivated influenza split vaccine in patients with ankylosing spondylitis and psoriatic arthritis
  nork: M. M. Baranova, et al.
  Argitaratua: (2024-06-01)
• Immunogenicity and safety of an inactivated enterovirus 71 vaccine coadministered with trivalent split-virion inactivated influenza vaccine: A phase 4, multicenter, randomized, controlled trial in China
  nork: Yaping Chen, et al.
  Argitaratua: (2022-12-01)
• A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries
  nork: Margaret Haugh, et al.
  Argitaratua: (2017-06-01)